Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors (CXCessoR4)

Clinical Trial ID NCT02472977

PubWeight™ 3.89‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02472977

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biol Med 2016 0.84
2 Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity. Cell Metab 2016 0.82
3 Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel? ESMO Open 2016 0.77
4 Molecular therapeutics in pancreas cancer. World J Gastrointest Oncol 2016 0.75
5 A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts. Oncotarget 2016 0.75
Next 100